LAVA Therapeutics N.V. (LVTX)
After hours:
| Previous Close | 2.9000 |
| Open | 2.8900 |
| Bid | 2.8000 x 100 |
| Ask | 2.9400 x 100 |
| Day's Range | 2.8300 - 2.9799 |
| 52 Week Range | 1.1310 - 6.4700 |
| Volume | |
| Avg. Volume | 1,125,645 |
| Market Cap | 75.976M |
| Beta (5Y Monthly) | 0.63 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.5700 |
| Earnings Date | Jun 06, 2024 - Jun 10, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Simply Wall St.LAVA Therapeutics Full Year 2023 Earnings: Revenues Disappoint
LAVA Therapeutics ( NASDAQ:LVTX ) Full Year 2023 Results Key Financial Results Net loss: US$42.0m (loss widened by 32...
GlobeNewswireLAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results
LAVA-1207 progressing in Phase 1/2a study, with pembrolizumab combination expected to begin in Q2 2024In March 2024, Pfizer paid LAVA $7 million for achieving a clinical milestone for EGFRd2 (PF-08046052/formerly LAVA-1223) LAVA 1266 tracking to Q2 2024 IND submission Strong balance sheet with cash of $95.6 million supports runway into 2026 UTRECHT, The Netherlands and PHILADELPHIA, March 20, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage
- GlobeNewswire
LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)
Milestone triggered by clinical progress in Phase 1 study, initiated in Q4 2023UTRECHT, The Netherlands and PHILADELPHIA, March 05, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, today announced that Pfizer has achieved a clinical development milestone for PF-08046052 (formerly SGN-EGFRd2 /LAVA-1223), prompting the first milestone
